Compare PCSA & BLIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCSA | BLIN |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 9.2M |
| IPO Year | 2012 | 2018 |
| Metric | PCSA | BLIN |
|---|---|---|
| Price | $2.13 | $0.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $25.00 | $4.62 |
| AVG Volume (30 Days) | 45.4K | ★ 69.1K |
| Earning Date | 01-01-0001 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,000.00 | ★ $13,568,000.00 |
| Revenue This Year | N/A | $22.67 |
| Revenue Next Year | N/A | $21.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $0.69 |
| 52 Week High | $8.88 | $2.22 |
| Indicator | PCSA | BLIN |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 53.44 |
| Support Level | $0.21 | $0.69 |
| Resistance Level | $2.56 | $0.90 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.75 | 43.61 |
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.